Latigo Biotherapeutics Inc(LTGO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 55.55% | Shs Outstand | 66.3M | Perf Week | 16.71% |
| Market Cap | 1.08B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.77% | Shs Float | 29.5M | Perf Month | -21.52% |
| Enterprise Value | 1.35B | PEG | - | EPS next Q | -0.63 | Inst Own | 14.78% | Short Float | 2.82% | Perf Quarter | - |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 14.87% | Short Ratio | 2.28 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.83M | Perf YTD | -22.19% |
| Book/sh | -4.16 | P/C | 19.63 | EPS past 3/5Y | - | ROE | - | 52W High | -36.98% ($25.93) | Perf Year | - |
| Cash/sh | 0.83 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 21.06% ($13.50) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 9.29% 8.59% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.42 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.15 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 47.18 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.15 | Sales Q/Q | - | SMA20 | 2.33% ($15.97) | Beta | - | Target Price | $52.25 |
| Payout | - | Debt/Eq | 2.5 | Earnings | 2026/9/3 | SMA50 | -16.56% ($19.58) | Rel Volume | 0.48 | Prev Close | $15.25 |
| Employees | - | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | - | SMA200 | -16.28% ($19.52) | Avg Volume(3M) | 0.37M | Price | $16.34 |
| IPO | 2026/8/7 | Option/Short | No/Yes | Trades | 1927 | Volume | 173,764 | Change | 7.15% |
💊 A US clinical-stage biotech company developing non-opioid painkiller candidates with low addiction risk. The company is pursuing a development strategy targeting both acute and chronic pain, centered on oral candidates that selectively inhibit sodium ion channels involved in pain signal transmission.
Over the past 1 year, on the lower side
37% below its 1-year high.
Traded less than usual. That is 48% of its average volume.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 14.8%.
Tap to view numbers
It ranks #151 of 595 in the industry
Based on market cap of $1B.
VSTM#148 Verastem Inc $1B PER - 
AVLN#149 Avalyn Pharma Inc $1B PER - 
REPL#150 Replimune Group Inc $1B PER - LTGO#151 Latigo Biotherapeutics Inc $1B PER - 
SPTX#152 Seaport Therapeutics Inc $1B PER - 
FAQ
What kind of company is LTGO?
LTGO belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LTGO?
The market cap of LTGO is approximately $1.1B, ranking 2,522 within its sector.
What is the 52-week high and low for LTGO?
LTGO has recorded a 52-week high of $25.93 and a low of $13.50.
